Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
T) therapy are two milestone achievements in clinical immunotherapy. However, both show …
New cell sources for CAR-based immunotherapy
M Mazinani, F Rahbarizadeh - Biomarker Research, 2023 - Springer
Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are
engineered to recognize and kill cancer cells, has achieved striking success in some …
engineered to recognize and kill cancer cells, has achieved striking success in some …
Macrophages derived from pluripotent stem cells: prospective applications and research gaps
I Lyadova, A Vasiliev - Cell & Bioscience, 2022 - Springer
Induced pluripotent stem cells (iPSCs) represent a valuable cell source able to give rise to
different cell types of the body. Among the various pathways of iPSC differentiation, the …
different cell types of the body. Among the various pathways of iPSC differentiation, the …
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
MC Wheless, M Comer, MK Gibson - Current Oncology Reports, 2024 - Springer
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction
Adenocarcinoma | Current Oncology Reports Skip to main content SpringerLink Account Menu …
Adenocarcinoma | Current Oncology Reports Skip to main content SpringerLink Account Menu …
Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches
N Unver - Clinical and Experimental Medicine, 2023 - Springer
Studies have begun to employ macrophages engineered with chimeric antigen receptor
(CAR-Macs) against solid tumors since they can enter solid tumor tissue and interact with …
(CAR-Macs) against solid tumors since they can enter solid tumor tissue and interact with …
Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics
L Hu, X Wang, Z Song, F Chen, B Wu - Molecular Medicine, 2024 - Springer
Background Pancreatic cancer is known for its poor prognosis and resistance to
conventional therapies, largely due to the presence of cancer stem cells (CSCs) and …
conventional therapies, largely due to the presence of cancer stem cells (CSCs) and …
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges
J Wu - BioDrugs, 2024 - Springer
Immune checkpoint inhibitor (ICI)-based therapy has made an unprecedented impact on
survival benefit for a subset of cancer patients; however, only a subset of cancer patients is …
survival benefit for a subset of cancer patients; however, only a subset of cancer patients is …
FLT3 signaling augments macrophage production from human pluripotent stem cells
K Kitajima, M Shingai, H Ando… - International Immunology, 2024 - academic.oup.com
Recent advances in cell engineering technologies enable immune cells to be utilized for
adoptive cell transfer (ACT) immunotherapy against cancers. Macrophages have the …
adoptive cell transfer (ACT) immunotherapy against cancers. Macrophages have the …
[HTML][HTML] CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar
K Chen, M Liu, J Wang, S Fang - Biomolecules and Biomedicine, 2024 - ncbi.nlm.nih.gov
Adoptive cell therapy (ACT) has been demonstrated to be one of the most promising cancer
immunotherapy strategies due to its active antitumor capabilities in vivo. Engineering T cells …
immunotherapy strategies due to its active antitumor capabilities in vivo. Engineering T cells …